How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

36,446 results for

Blood Transfusion

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Evaluation of serum markers for improved detection of autologous blood transfusions Full Text available with Trip Pro

Evaluation of serum markers for improved detection of autologous blood transfusions 29674501 2018 11 14 1592-8721 103 10 2018 Oct Haematologica Haematologica Evaluation of serum markers for improved detection of autologous blood transfusions. e443-e445 10.3324/haematol.2018.190918 Cox Holly D HD Sports Medicine Research and Testing Laboratory, Salt Lake City, UT, USA hcox@smrtl.org. Miller Geoffrey D GD Sports Medicine Research and Testing Laboratory, Salt Lake City, UT, USA. University of Utah (...) . University of Utah School of Medicine - Division of Physical Medicine and Rehabilitation, Salt Lake City, UT, USA. eng Letter 2018 04 19 Italy Haematologica 0417435 0390-6078 2018 4 21 6 0 2018 4 21 6 0 2018 4 21 6 0 ppublish 29674501 haematol.2018.190918 10.3324/haematol.2018.190918 PMC6165801 Eur J Appl Physiol. 2011 Sep;111(9):2307-14 21336951 Blood. 2011 Sep 1;118(9):2395-404 21652677 J Clin Invest. 2017 Jan 3;127(1):375-382 27941245 Blood. 2011 Dec 15;118(25):6675-82 22021369 Anal Biochem. 2009 Jun

2018 Haematologica

2. Luspatercept–aamt (Reblozyl) - For the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions

Luspatercept–aamt (Reblozyl) - For the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions Drug Approval Package: REBLOZYL (luspatercept-aamt) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: REBLOZYL (luspatercept-aamt) Company: Celgene Corporation Application Number: 761136 Approval Date: 11/08/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

2020 FDA - Drug Approval Package

3. D-immunized blood donors who are female and who possess at least one HLA-DRB1*15 allele show a propensity for high serum RhIG production. (Abstract)

D-immunized blood donors who are female and who possess at least one HLA-DRB1*15 allele show a propensity for high serum RhIG production. D- individuals with previous D-incompatible pregnancies and/or blood transfusions, as well as those who are actively immunized with small-volume D+ red blood cells (RBCs), are stimulated to produce RhIG. Many factors could influence the stimulation of immunoglobulin production in response to foreign antigen (such as antigen immunogenicity and genetic factors (...) ), and it is unknown whether genetic markers could potentially identify responder anti-D donors.Anti-D donors were assigned a responder profile based on their serum RhIG levels (n = 431). A subset of donors (n = 272) had DNA extracted for polymerase chain reaction genotyping assays for target genes in antigen presentation and pathogen recognition receptors (TLR2, TLR4, CD14, FcγRIIA, and the MHC Class II locus HLA-DRB1). Statistical tests for associations between anti-D donor responder profiles and genetic factors

2018 Transfusion

4. Transfusion of red blood cells stored for shorter versus longer duration for all conditions. Full Text available with Trip Pro

Transfusion of red blood cells stored for shorter versus longer duration for all conditions. Red blood cell (RBC) transfusion is a common treatment for anaemia in many conditions. The safety and efficacy of transfusing RBC units that have been stored for different durations before a transfusion is a current concern. The duration of storage for a RBC unit can be up to 42 days. If evidence from randomised controlled trials (RCT) were to indicate that clinical outcomes are affected by storage (...) duration, the implications for inventory management and clinical practice would be significant.To assess the effects of using red blood cells (RBCs) stored for a shorter versus a longer duration, or versus RBCs stored for standard practice duration, in people requiring a RBC transfusion.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, CINAHL, PubMed (for epublications), LILACS, Transfusion Evidence Library, Web of Science CPCI-S and four international clinical

2018 Cochrane

5. Absence of giant blood Marseille-like virus DNA detection by polymerase chain reaction in plasma from healthy US blood donors and serum from multiply transfused patients from Cameroon. (Abstract)

Absence of giant blood Marseille-like virus DNA detection by polymerase chain reaction in plasma from healthy US blood donors and serum from multiply transfused patients from Cameroon. A new Marseilleviridae virus family member, giant blood Marseille-like (GBM) virus, was recently reported in persons from France in the serum of an infant with adenitis, in the blood of 4% of healthy blood donors, and in 9% of multiply transfused thalassemia patients. These results suggested the presence (...) of a nucleocytoplasmic large DNA virus potentially transmissible by blood product transfusion.To investigate this possibility we tested the plasma from 113 US blood donors and 74 multiply transfused Cameroon patients for GBM viral DNA using highly sensitive polymerase chain reaction (PCR) assays.GBM DNA was not detected by nested PCR in any of these 187 human specimens.Further testing is required to confirm the occurrence of human GBM virus infections.© 2015 AABB.

2015 Transfusion

6. Blood Product Transfusions Prior to Surgical Interventions: Clinical Effectiveness and Guidelines

Blood Product Transfusions Prior to Surgical Interventions: Clinical Effectiveness and Guidelines Blood Product Transfusions Prior to Surgical Interventions: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Blood Product Transfusions Prior to Surgical Interventions: Clinical Effectiveness and Guidelines Blood Product Transfusions Prior to Surgical Interventions: Clinical Effectiveness and Guidelines Last updated: December 11, 2018 Project Number: RB1285-000 Product (...) Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of plasma or prothrombin complex concentrate transfusions prior to surgical procedures in individuals with an elevated international normalized ratio? What is the evidence for the safety of undergoing surgical procedures for individuals with an elevated international normalized ratio? What are the evidence-based guidelines regarding pre-surgical transfusion considerations

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Blood Transfusion in Trauma: Timing and Product Ratio

Blood Transfusion in Trauma: Timing and Product Ratio Emergency Medicine > Journal Club > Archive > February 2018 Toggle navigation February 2018 Blood Transfusion in Trauma: Timing and Product Ratio Vignette It's an active early spring afternoon in the city, and you're pretty sure that just about everyone and their sister have been shot at, with most of the pour souls ending up in your TCC. As these things tend to go, The GSWs thus far are to the extremities or benign grazes (...) : Trauma patients requring urgent blood transfusion or meeting massive transfusion protocol (MTP) criteria. Intervention #1: Balanced blood transfusion (closer to a 1:1:1 ratio of plasma:platelets:RBCs) Comparison #2: Higher blood to plasma/platelet ratio (i.e. closer to 1:1:2) Intervention #2 : Prehospital blood transfusion by EMS Comparison #2: No prehospital blood transfusion Outcome: Mortality, incidence of transfusion reaction, cost, hospital/ICU length of stay Articles Article 1: Article 2

2018 Washington University Emergency Medicine Journal Club

9. Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias. Full Text available with Trip Pro

Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias. Non-transfusion dependent beta thalassaemia is a subset of inherited haemoglobin disorders characterised by reduced production of the beta globin chain of the haemoglobin molecule leading to anaemia of varying severity. Although blood transfusion is not a necessity for survival, it is required when episodes of chronic anaemia occur. This chronic anaemia can impair growth and affect quality of life (...) . People with non-transfusion dependent beta thalassaemia suffer from iron overload due to their body's increased capability of absorbing iron from food sources. Iron overload becomes more pronounced in those requiring blood transfusion. People with a higher foetal haemoglobin level have been found to require fewer blood transfusions. Hydroxyurea has been used to increase foetal haemoglobin level; however, its efficacy in reducing transfusion, chronic anaemia complications and its safety need

2016 Cochrane

10. Effect of Umbilical Cord Blood Sampling versus Admission Blood Sampling on Requirement of Blood Transfusion in Extremely Preterm Infants: A Randomized Controlled Trial (Abstract)

Effect of Umbilical Cord Blood Sampling versus Admission Blood Sampling on Requirement of Blood Transfusion in Extremely Preterm Infants: A Randomized Controlled Trial To evaluate the effect of blood sampling from the placental end of the umbilical cord compared with initial blood sampling from neonates, on the need for first packed red blood cell transfusion in extremely preterm infants. We hypothesized that cord blood sampling could delay the time to first blood transfusion.In this single (...) transfusion, and was compared using survival analysis.Eighty neonates were enrolled. The time to first transfusion was significantly delayed in the cord sampling group (30 vs 14 days, hazard ratio: 0.44, [95% CI 0.27-0.72], P < .001). Fewer neonates in the cord sampling group were transfused in the first 28 days of life (30% vs 75%, P < .001). Overall transfusion requirements and other clinical outcomes were similar in the groups.Initial blood sampling from placental end of umbilical cord, when combined

2019 EvidenceUpdates

11. Prophylactic intravenous calcium therapy for exchange blood transfusion in the newborn. Full Text available with Trip Pro

Prophylactic intravenous calcium therapy for exchange blood transfusion in the newborn. Exchange blood transfusion (EBT) is a form of whole blood transfusion in which the total blood volume is replaced within a few hours. In perinatal and neonatal medicine, EBT is most often used in the management of severe anaemia or severe hyperbilirubinaemia in the first week of life. Hypocalcaemia, one of the common morbidities associated with EBT, is thought to arise from the chelating effects (...) of the citrate commonly used as an anticoagulant in the donor's blood. This disorder manifests with muscular and nervous irritability and cardiac arrhythmias.To determine whether the use of prophylactic calcium reduces the risk of hypocalcaemia-related morbidities and death among newborn infants receiving EBT.We used the standard search strategy of the Cochrane Neonatal Review group to search the Cochrane Central Register of Controlled Trials (CENTRAL 2016, Issue 5), MEDLINE via PubMed (1966 to 29 June 2016

2017 Cochrane

12. Detection of Merkel Cell Polyomavirus DNA in Serum Samples of Healthy Blood Donors Full Text available with Trip Pro

Detection of Merkel Cell Polyomavirus DNA in Serum Samples of Healthy Blood Donors Merkel cell polyomavirus (MCPyV) has been detected in 80% of Merkel cell carcinomas (MCC). In the host, the MCPyV reservoir remains elusive. MCPyV DNA sequences were revealed in blood donor buffy coats. In this study, MCPyV DNA sequences were investigated in the sera (n = 190) of healthy blood donors. Two MCPyV DNA sequences, coding for the viral oncoprotein large T antigen (LT), were investigated using (...) from blood donors could represent a potential vehicle for MCPyV infection in receivers, whereas an increase in viral load may occur with multiple blood transfusions. In certain patient conditions, such as immune-depression/suppression, additional disease or old age, transfusion of MCPyV-positive samples could be an additional risk factor for MCC onset.

2017 Frontiers in oncology

13. Characteristics of Potential Protein Biomarkers Extracted with 10% TCA from Blood Serum of Non-Hodgkin’s Lymphoma and Multiple Myeloma Patients Full Text available with Trip Pro

Characteristics of Potential Protein Biomarkers Extracted with 10% TCA from Blood Serum of Non-Hodgkin’s Lymphoma and Multiple Myeloma Patients 29988205 2018 11 14 2251-9637 6 4 2017 Fall International journal of molecular and cellular medicine Int J Mol Cell Med Characteristics of Potential Protein Biomarkers Extracted with 10% TCA from Blood Serum of Non-Hodgkin's Lymphoma and Multiple Myeloma Patients. 235-238 10.22088/BUMS.6.4.235 Myronovskij Severyn S Department of Regulation of Cell (...) Proliferation and Apoptosis, Institute of Cell Biology, National Academy of Sciences of Ukraine, Lviv, Ukraine . Shalay Olga O Laboratory of Immunocytology and Genetics of Blood Tumors , Institute of Blood Pathology and Transfusion Medicine, National Academy of Medical Sciences of Ukraine, Lviv, Ukraine. Spivak Veronika V Biological Faculty of Ivan Franko Lviv National University, Lviv, Ukraine. Stoika Rostyslav R Department of Regulation of Cell Proliferation and Apoptosis, Institute of Cell Biology

2017 International journal of molecular and cellular medicine

14. Inflammatory cytokines in serum samples of healthy blood donors. (Abstract)

Inflammatory cytokines in serum samples of healthy blood donors. 27475802 2017 03 27 2017 03 27 1473-0502 55 2 2016 Oct Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Transfus. Apher. Sci. Inflammatory cytokines in serum samples of healthy blood donors. 246-247 S1473-0502(16)30088-X 10.1016/j.transci.2016.07.020 Sellberg Felix F Department of Immunology, Genetics and Pathology, Section (...) Trial 2016 07 21 England Transfus Apher Sci 101095653 1473-0502 0 Cytokines 0 Inflammation Mediators T Blood Donors Cytokines blood Female Humans Inflammation Mediators blood Male 2016 07 14 2016 07 18 2016 10 19 6 0 2017 3 28 6 0 2016 8 1 6 0 ppublish 27475802 S1473-0502(16)30088-X 10.1016/j.transci.2016.07.020

2017 Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Controlled trial quality: uncertain

15. Blood and Clots Series: What are the complications of transfusion? What symptoms/signs should I worry about?

Blood and Clots Series: What are the complications of transfusion? What symptoms/signs should I worry about? Blood and Clots Series: What are the complications of transfusion? What symptoms/signs should I worry about? - CanadiEM Blood and Clots Series: What are the complications of transfusion? What symptoms/signs should I worry about? In , by Matthew Nicholson July 30, 2018 All the content from the Blood & Clots series can be found . CanMEDS Roles addressed: Medical Expert, Communicator (...) normalizing. Reticulocyte count is 45. There are no signs of bleeding clinically or on ultrasound examination of the abdomen. There is no laboratory evidence of hemolysis. You suspect the patient may be unable to produce adequate RBCs due to inflammation from her injuries and operation. To be safe you send investigations to check nutritional parameters and start folic acid empirically. The patient complains of fatigue and you decide a blood transfusion is indicated. The situation is no longer emergent

2018 CandiEM

16. Blood and Clots Series: Massive transfusion protocol: what is it, why does it exist, and when should I call one?

Blood and Clots Series: Massive transfusion protocol: what is it, why does it exist, and when should I call one? Blood and Clots Series: Massive transfusion protocol: what is it, why does it exist, and when should I call one? - CanadiEM Blood and Clots Series: Massive transfusion protocol: what is it, why does it exist, and when should I call one? In , by Matthew Nicholson July 16, 2018 All the content from the Blood & Clots series can be found . CanMEDS Roles addressed: Medical Expert Case (...) administration and minimize coagulopathy by administering RBCs, platelets, and plasma in a balanced ratio (approximating 1:1:1 or 1:1:2 per the PROPPR trial) 7 . Administration of either cryoprecipitate or fibrinogen concentrate are also common in MTP. Key Concepts in MTPs The patient remains tachycardic with labile blood pressure despite two units of RBCs and two litres of crystalloid. You decide to activate the hospital’s massive transfusion protocol prior to the results of laboratory tests becoming

2018 CandiEM

17. Red blood cell transfusions are associated with lower mortality in patients with severe sepsis and septic shock: A propensity-matched analysis

Red blood cell transfusions are associated with lower mortality in patients with severe sepsis and septic shock: A propensity-matched analysis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2017 PedsCCM Evidence-Based Journal Club

18. Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion

Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2017 PedsCCM Evidence-Based Journal Club

19. Seroprevalence of transfusion transmitted infections among blood donors in Gash Barka Zonal Blood Transfusion Center, Barentu, Eritrea, 2014 through 2017. Full Text available with Trip Pro

Seroprevalence of transfusion transmitted infections among blood donors in Gash Barka Zonal Blood Transfusion Center, Barentu, Eritrea, 2014 through 2017. Transfusion-transmissible infections pose a major health risk in developing countries, including Eritrea. In the present study, we sought to determine the prevalence of specific transfusion transmitted infections (TTIs) and the associated risk factors among blood donors at a newly established regional blood transfusion center in Barentu (...) , Eritrea.The seroprevalence of markers for specific TTIs by sex, age, educational status, residence, occupation, and donor type was evaluated for donors who donated blood between July 2014 and April 2017. The relationship between TTIs and the stated factors was evaluated using the Pearson Chi-square test/Fishers exact test. Adjusted and unadjusted binary logistic regression models were employed to estimate the odds ratio (OR) and 95% confidence interval (CI) for the occurrence of TTIs. A two-sided p-value

2019 BMC Hematology

20. Phenobarbital and Phototherapy Combination Enhances Decline of Total Serum Bilirubin and May Decrease the Need for Blood Exchange Transfusion in Newborns with Isoimmune Hemolytic Disease. Full Text available with Trip Pro

Phenobarbital and Phototherapy Combination Enhances Decline of Total Serum Bilirubin and May Decrease the Need for Blood Exchange Transfusion in Newborns with Isoimmune Hemolytic Disease. The objective of this study was to evaluate the effect of phenobarbital and phototherapy combination on the total serum bilirubin of the newborn infants with isoimmune hemolytic disease (IHD) and its impact on blood exchange transfusion rates.This single-blinded, prospective, randomized, controlled trial (...) completed the study: 97 infants were included in group 1 and 89 infants in group 2. The difference between the mean total serum bilirubin levels at 24, 48, and 72 hours after starting the trial was clinically and statistically significant at P < 0.05. The differences between the two groups were also statistically significant at P < 0.05. Of the total 186 who completed the study, only 22 underwent blood exchange transfusion [7 from group 1, and 15 from group 2 (P = 0.0478)].In a limited-resources setting

2015 Clinical medicine insights. Pediatrics Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>